Identification and Validation of the lncRNA BACE1-AS as Immune-Related Influencing Factor in Tumorigenesis following Pan-Carcinoma Analysis

Table 1

Clinical features of pan-cancer from TCGA database.

Abbreviation	Tumor type	Normal	Tumor	Female	Male	Average age
ACC	Adrenocortical carcinoma	0	79	48	31	46.70
BLCA	Bladder urothelial carcinoma	19	408	114	313	68.17
BRCA	Breast invasive carcinoma	113	1097	1197	13	58.21
CESC	Cervical squamous cell carcinoma and endocervical adenocarcinoma	3	306	309	0	48.30
CHOL	Cholangiocarcinoma	9	36	23	22	64.56
COAD	Colon adenocarcinoma	35	461	234	262	67.51
DLBC	Lymphoid neoplasm diffuse large B cell lymphoma	0	48	26	22	56.27
ESCA	Esophageal carcinoma	11	162	29	144	63.82
GBM	Glioblastoma multiforme	5	161	62	104	55.06
HNSC	Head and neck squamous cell carcinoma	44	502	152	394	60.87
KICH	Kidney chromophobe	24	65	38	51	52.60
KIRC	Kidney renal clear cell carcinoma	72	531	217	386	61.54
KIRP	Kidney renal papillary cell carcinoma	32	289	88	233	61.35
LAML	Acute myeloid leukemia	0	151	68	83	50.00
LIHC	Liver hepatocellular carcinoma	50	374	141	233	59.79
LUAD	Lung adenocarcinoma	59	515	309	265	65.44
LUSC	Lung squamous cell carcinoma	49	501	143	407	67.50
MESO	Mesothelioma	0	86	15	71	62.95
OV	Ovarian serous cystadenocarcinoma	0	379	379	0	60.16
PAAD	Pancreatic adenocarcinoma	4	178	79	103	65.10
PCPG	Pheochromocytoma and paraganglioma	3	183	103	83	47.32
PRAD	Prostate adenocarcinoma	52	496	0	548	60.87
READ	Rectum adenocarcinoma	10	166	84	92	64.19
SARC	Sarcoma	2	263	145	121	61.12
SKCM	Skin cutaneous melanoma	1	471	179	293	58.15
STAD	Stomach adenocarcinoma	32	375	161	246	66.32
TGCT	Testicular germ cell tumors	0	139	0	139	31.87
THCA	Thyroid carcinoma	58	510	414	154	47.02
THYM	Thymoma	2	119	60	61	57.91
UCEC	Uterine corpus endometrial carcinoma	35	532	567	0	63.68
UCS	Uterine carcinosarcoma	0	56	56	0	69.77
UVM	Uveal melanoma	0	80	35	45	61.65